Cargando…
Effect of enzalutamide on PK of P‐gp and BCRP substrates in cancer patients: CYP450 induction may not always predict overall effect on transporters
Drug‐drug interaction (DDI) is an important consideration for clinical decision making in prostate cancer treatment. The objective of this study was to evaluate the effect of enzalutamide, an oral androgen receptor inhibitor, on the pharmacokinetics (PK) of digoxin (P‐glycoprotein [P‐gp] probe subst...
Autores principales: | Poondru, Srinivasu, Ghicavii, Vitalii, Khosravan, Reza, Manchandani, Pooja, Heo, Nakyo, Moy, Selina, Wojtkowski, Tomasz, Patton, Melanie, Haas, Gabriel P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9099123/ https://www.ncbi.nlm.nih.gov/pubmed/35118821 http://dx.doi.org/10.1111/cts.13229 |
Ejemplares similares
-
Physiologically-based pharmacokinetic modeling to predict drug-drug interaction of enzalutamide with combined P-gp and CYP3A substrates
por: Otsuka, Yukio, et al.
Publicado: (2023) -
Recent advances in the search of BCRP- and dual P-gp/BCRP-based multidrug resistance modulators
por: Dei, Silvia, et al.
Publicado: (2019) -
Evaluation of drug interaction potential of zanubrutinib with cocktail probes representative of CYP3A4, CYP2C9, CYP2C19, P‐gp and BCRP
por: Ou, Ying C., et al.
Publicado: (2021) -
Cannabidiol changes P-gp and BCRP expression in trophoblast cell lines
por: Feinshtein, Valeria, et al.
Publicado: (2013) -
Dual Inhibition of P-gp and BCRP Improves Oral Topotecan Bioavailability in Rodents
por: Lee, Jaeok, et al.
Publicado: (2021)